甲苯磺酸尼拉帕利胶囊致极重度血小板减少1例分析

doi:10.19803/j.1672-8629.20260261

摘要/Abstract

摘要： 目的探讨甲苯磺酸尼拉帕利胶囊（以下简称“尼拉帕利胶囊”）致极重度血小板减少病例,为临床安全用药提供参考。方法分析1例患者服用尼拉帕利胶囊后出现极重度血小板减少病例,查阅国内外相关文献对血小板减少原因及临床应对策略进行探讨。结果经关联性评价,患者出现极重度血小板减少与服用尼拉帕利胶囊有关,停药并对症处理后血小板计数回升,出血症状消失。结论尼拉帕利胶囊临床应用中可诱发极重度血小板减少。临床用药期间需规律监测血常规指标,一旦发现血小板异常降低或出血相关症状,需即刻停药并采取针对性治疗措施,保障患者用药安全。

关键词: 甲苯磺酸尼拉帕利胶囊, 聚腺苷二磷酸核糖聚合酶抑制剂, 血小板减少, 卵巢肿瘤, 药品不良反应

Abstract: Objective To investigate a case of extremely severe thrombocytopenia induced by niraparib tosilate capsules and to provide a reference for its safe clinical use. Methods One case of extremely severe thrombocytopenia after taking niraparib was analyzed, and the causes of thrombocytopenia and clinical management strategies were reviewed based on related literature. Results Based on a correlation evaluation, the patient’s extremely severe thrombocytopenia was believed to have been caused by niraparib. After discontinuation of the drug and symptomatic treatment, the platelet count returned to normal and bleeding symptoms were resolved. Conclusion Niraparib may cause severe thrombocytopenia during clinical use. Routine monitoring with complete blood counts is recommended during treatment. If a significant decrease in platelet count occurs or bleeding-related symptoms are observed, the drug should be discontinued immediately and appropriate treatments offered to ensure patients’ safety and prevent serious adverse reactions.

Key words: Niraparib Tosilate Capsules, Poly ADP-Ribose Polymerase Inhibitors, Thrombocytopenia, Ovarian Neoplasms, Adverse Drug Reaction

中图分类号:

R994.11

靳小倩, 何志洁. 甲苯磺酸尼拉帕利胶囊致极重度血小板减少1例分析[J]. 中国药物警戒, 2026, 23(7): 823-825.

Jin Xiaoqian, He Zhijie. One case of extremely severe thrombocytopenia caused by niraparib tosilate capsules[J]. Chinese Journal of Pharmacovigilance, 2026, 23(7): 823-825.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20260261

https://zgywjj.magtechjournal.com/CN/Y2026/V23/I7/823

参考文献

[1] Kong Beihua, Liu Jihong, Cui heng, et al. Guidelines for clinical application of PARP inhibitors in ovarian cancer (2025 edition)[J]. Progress in Obstetrics and Gynecology(现代妇产科进展), 2025, 34(2): 81-94.
[2] National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: ovarian cancer including fallopian tube cancer and primary peritoneal cancer (version 1.2025)[EB/OL]. (2024-12-15)[2025-12-15]. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1453.
[3] González-Martín A, Harter P, Leary A, et al.Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up[J]. Annals of Oncology, 2023, 34(10): 833-848.
[4] Chen Rong.A case of severe thrombocytopenia induced by niraparib tosylate capsules[J]. Chinese Journal of Pharmacoepidemiology(药物流行病学杂志), 2022, 31(11): 778-779.
[5] Xu Yanyan, Yao Min, Guo Xiaohong.A case of severe thrombocy-topenia induced by niraparib[J]. Jiangsu Medical Journal(江苏医药), 2022, 48(5): 539-540.
[6] Chen M, Zhou L, Yang H, et al.Niraparib-related severe refractory thrombocytopenia in ovarian cancer patients receiving paclitaxel/carboplatin chemotherapy: a report on three cases[J]. Int J Clin Pharmacol Ther, 2025, 63(4): 169-173.
[7] Tayyab M, Butt Z A, Kamala K P, et al.Safety of niraparib-based regimens in patients with ovarian cancer: a systematic review and meta-analysis[J]. Eur J Obstet Gynecol Reprod Biol, 2025, 307: 121-127.
[8] Shah Rushi, Vemula S S M, Kotla N K, et al. Hematologic toxicities associated with PARP inhibitors: real-world pharmacovigilance study using the FAERS database with era-trend evaluation and serious outcome modeling[J]. Blood, 2025, 146(Suppl 1): 4474.
[9] Dai M F, Wang X, Xin W X, et al.Safety and hematological toxicities of PARP inhibitors in patients with cancer: a systematic review of randomized controlled trials and a pharmacovigilance analysis[J]. Expert Review of Anticancer Therapy, 2024, 24(7): 613-622.
[10] Kimura M, Yamada S, Matsuyama R, et al.Factors influencing severe hematologic toxicity following niraparib therapy in patients with ovarian cancer[J]. Cancer Diagnosis & Prognosis, 2025, 5(3): 378-385.
[11] Guo Ling, Wang Yili, Song Yanfang, et al.A case of acquired amega-karyocytic thrombocytopenic purpura caused by niraparib[J]. J Cancer Control Treat(肿瘤预防与治疗), 2024, 37(3): 264-270.
[12] Guan Q, Aktar J S, Pataky E R, et al.Real-world safety of niraparib for maintenance treatment of ovarian cancer in Canada[J]. Current Oncology, 2024, 31(6): 3591-3602.
[13] Center for Drug Evaluation, National Medical Products Administration. Technical guidance for clinical evaluation of adverse event relevance in clinical trials (for trial implementation)[S]. Beijing: Center for Drug Evaluation, 2024.
[14] National Medical Products Administration. National medical products administration conditionally approves the marketing of ovarian cancer treatment drug niraparib tosylate capsules[EB/OL]. (2019-12-27)[2025-11-25]. https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/20191227191601479.html.
[15] Naranjo C A, Busto U, Sellers E M, et al.A method for estimating the probability of adverse drug reactions[J]. Clin Pharmacol Ther, 1981, 30(2): 239-245.
[16] Wang Qiru, Zuo Li, Du Qiong, et al.Pharmaceutical care of a patient with gradeⅣmyelosuppression induced by olaparib[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2023, 20(10): 1176-1180.
[17] Armstrong D K, Alvarez R D, Backes F J, et al. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer: NCCN clinical practice guidelines in oncology (version 3.2025)[EB/OL]. (2025-07-16)[2025-11-25]. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1413.
[18] Tew W P, Lacchetti C, Kohn E C, et al.Poly(ADP-ribose) polymerase inhibitors in the management of ovarian cancer: ASCO guideline rapid recommendation update[J]. J Clin Oncol, 2022, 40(33): 3878-3881.
[19] Scott C L, Swisher E M, Kaufmann S H.Poly(ADP-ribose) polymerase inhibitors: recent advances and future development[J]. J Clin Oncol, 2015, 33(12): 1397-1406.
[20] González- Martín A, Pothuri B, Vergote I, et al.Niraparib in patients with newly diagnosed advanced ovarian cancer[J]. The New England Journal of Medicine, 2019, 381(25): 2391-2402.
[21] Mirza M R, Monk B J, Lund B, et al.Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer[J]. The New England Journal of Medicine, 2016, 375(22): 2154-2164.
[22] Moore K N, Secord A A, Geller M A, et al.Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial[J]. The Lancet Oncology, 2019, 20(5): 636-648.
[23] Roxo F, Duarte D, Abreu M H.Immune-mediated thrombocytopenia induced by niraparib: a clinically relevant case[J]. Cureus, 2025, 17(11): e97299.
[24] Maiorano B A, Catalano M, Maiorano M F P, et al. Hematological toxicity of PARP inhibitors in solid tumors: a systematic review and safety meta-analysis[J]. Cancer Metastasis Rev, 2025, 44(3): 65.
[25] National Cancer Institute. Common terminology criteria for adverse events(CTCAE) v6.0[EB/OL]. (2025-07-22)[2025-12-25]. https://dctd.cancer.gov/research/ctep-trials/for-sites/adverse-events/ctcae-v6.pdf.